Latest Content

Fariha Abbasi-Feinberg, MD, discusses underdiagnosed sleep disorders, what a recent insomnia-stroke study does and doesn't prove, and where health plan policy still lags behind the evidence.

The Health Care Cost Institute’s annual healthcare cost and utilization report on healthcare spending by those with employer-based health insurance shows that price increases, not utilization, account for soaring cost increases. HCCI CEO Katie Martin says employers should focus on bringing down hospital prices.

An ophthalmic imaging specialist outlined how lighting technique and serial documentation help clinicians tell normal iris pigment from disease.

Neuro-ophthalmologists reviewed migraine diagnosis, a stepwise treatment ladder and migraine mimics that often present first in eye clinics.

Topical steroids remain first-line for chronic hand eczema, but long-term use can thin the skin and leave patients with poorly controlled disease.

Laura Ferris urges risk-based melanoma screening and highlights earlier immunotherapy, selective imaging, vaccine limits and new post–PD-1 options.

Patients with HS should get three to four months on a biologic before a switch, says a dermatologist who sees promise in oral JAK inhibitors.

With three FDA-approved biologics for hidradenitis suppurativa, Jennifer Hsiao, M.D., said patient preference and access often decide which comes first.

A structured approach grounded in implementation science and supported by a culture that values continuous improvement can enable organizations to identify barriers, align stakeholders and sustain new practices over time.

A session at AAO 2026 explained how Medicare, Medicare Advantage and commercial coverage policies differ in ophthalmology, and how practices can document and code to stay compliant

Presenters at AAO 2026 examined hospital eye coverage gaps, workforce strain and how ophthalmology can gain influence within health systems.

Price transparency data on 11 glaucoma surgery codes showed payer class was most consistently tied to price, with Medicaid and self-pay rates lowest.

Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.

Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.

The 2026 American Academy of Ophthalmology Meeting got started today in New Orleans with a mix of celebration and candor about the challenges facing ophthalmology today.

How LLM decision support reshapes dermatology care, helping non-specialists diagnose while navigating trust gaps, ambiguity, and hallucination risks at Fall Clinical Derm.

Real-world data at the 2026 Fall Clinical Dermatology Conference show dupilumab in children with atopic dermatitis cuts new allergies and asthma risk versus steroids.

Sagimet CEO David Happel shares insights on denifanstat, highlighting strong acne response, tolerability and optimism for a denifanstat U.S. trial.

Sagimet CEO David Happel says oral denifanstat could sharply cut antibiotic use in acne and be used before patients ever need isotretinoin.

Sagimet Biosciences’ denifanstat oral acne pill shows rapid, sustained lesion cuts and higher clear-skin rates in phase 3, offering an antibiotic-sparing option.

Implementation costs, structural pressures and the labor-intensive nature of healthcare mean that artificial intelligence is unlikely to dramatically lower its costs, at least in the short term.

Real-world research using the PEDISTAD registry makes up for the gap left by relatively low enrollment of children with skin of color in the pivotal trials of Dupixent (dupilumab).

New guidelines for acute low back pain favors self-care, NSAIDs, physical therapy and acupuncture over routine imaging and first-line opioids.

Breakthroughs in 2026 dermatology spotlight oral psoriasis drugs nearing biologics, weight-loss combos for PsA, personalized mRNA melanoma vaccines and expanding OTC acne options.

Direct-to-consumer drug programs hold the promise of cheaper GLP-1s and other drugs, but buying drugs outside insurance benefits may be more costly— and risky — in the long run.

The research results suggest that exposure to smoke may possibly tip the balance and trigger the onset of hidradenitis suppurativa in some children and adolescents

Alison Pritchard, Ph.D., of Kennedy Krieger Institute, explains how ADHD and sleep problems reinforce each other in children and why clinicians should set clear expectations with caregivers before treatment begins.

The trade group argues CMS exceeded its authority with GLOBE, a Medicare Part B model tying drug rebates to prices in 19 other countries.

Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.

The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.

In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.